Either genetic deletion of residue K280 (ΔK280), as observed in familial FTDP-17 dementia [11], or lysine acetylation on residue K280, as observed in AD and related tauopathies [3], may be sufficient to neutralize the positive charge within this region, thereby impairing tau-MT interactions. This evidence concerns the gene MAPT and Alzheimer disease.